Fidelity Disruptive Medicine ETF (FMED)
NASDAQ: FMED · Real-Time Price · USD
25.03
+0.37 (1.51%)
Dec 20, 2024, 4:00 PM EST - Market closed
1.51% (1D)
| Assets | $52.64M |
| Expense Ratio | 0.50% |
| PE Ratio | 39.53 |
| Shares Out | 2.12M |
| Dividend (ttm) | $0.00 |
| Dividend Yield | 0.00% |
| Ex-Dividend Date | Jun 21, 2024 |
| Payout Ratio | 0.16% |
| 1-Year Return | +6.24% |
| Volume | 6,259 |
| Open | 24.66 |
| Previous Close | 24.66 |
| Day's Range | 24.66 - 25.19 |
| 52-Week Low | 23.32 |
| 52-Week High | 26.68 |
| Beta | n/a |
| Holdings | 64 |
| Inception Date | Apr 16, 2020 |
About FMED
Fund Home PageThe Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is issued by Fidelity.
Top 10 Holdings
41.18% of assets| Name | Symbol | Weight |
|---|---|---|
| Boston Scientific Corporation | BSX | 6.52% |
| Fidelity Securities Lending Cash Central Fund | n/a | 5.15% |
| Intuitive Surgical, Inc. | ISRG | 4.55% |
| Insulet Corporation | PODD | 4.45% |
| UnitedHealth Group Incorporated | UNH | 4.07% |
| Danaher Corporation | DHR | 3.78% |
| argenx SE | ARGX | 3.58% |
| Exact Sciences Corporation | EXAS | 3.23% |
| Regeneron Pharmaceuticals, Inc. | REGN | 3.04% |
| Penumbra, Inc. | PEN | 2.81% |
News
As Biotech Outlook Grows Healthier, Look to Disruptive ETF FMED
Could now be the time to invest in biotech? The space, which performed well in 2020 and 2021, dropped off in the interim amid high interest rates and slowing deal-making.
8 days ago - ETF Trends
Why traditional active managers are joining the ETF space
Greg Friedman, head of ETF management and strategy at Fidelity Investments, joins 'Halftime Report' to discuss a spike in ETF flows going to active management, Fidelity's decision to convert mutual fu...
1 year ago - CNBC Television